Payment overview · 2025
General Payments
$1,616.21
91 reported records · 19 companies
Healthcare provider profile · identity verified
Jackie D Maxey, MD
Allopathic & Osteopathic Physicians|Family Medicine · LONDON, KY · NPI 1073525861
Verified facts
What the public records show
CMS Open Payments records show Jackie D Maxey, MD received $1,616.21 in general payments during 2025 across 91 reported records.
Novartis Pharmaceuticals Corporation accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 900 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Lantus by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $383.46 | 23.7% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.66 | 10.8% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $170.96 | 10.6% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.49 | 10.4% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.75 | 6.4% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $90.95 | 5.6% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $81.49 | 5.0% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $80.51 | 5.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $73.32 | 4.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.14 | 3.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $42.72 | 2.6% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$33.41 | 2.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.55 | 1.9% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $30.89 | 1.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.58 | 1.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.95 | 1.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.24 | 1.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.09 | 0.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $15.05 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,616.21 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $383.46 | 19 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $174.66 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $174.66 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $155.16 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $155.16 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $140.03 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $102.75 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $96.28 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $90.95 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $81.49 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $80.51 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $73.32 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $73.32 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $57.81 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.14 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $30.89 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $27.58 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.95 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 900 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 114 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 222 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 193 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
169 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
136 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
114 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
222 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
102 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
193 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
900 | 85 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
43 | 43 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 2177 | 201 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1867 | 211 |
| Amlodipine Besylate | Amlodipine Besylate | 1811 | 324 |
| Gabapentin | Gabapentin | 1343 | 161 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1326 | 219 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1257 | 184 |
| Donepezil Hcl | Donepezil Hcl | 1150 | 72 |
| Lisinopril | Lisinopril | 1015 | 198 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1002 | 129 |
| Eliquis | Apixaban | 900 | 85 |
| Divalproex Sodium | Divalproex Sodium | 876 | 42 |
| Lorazepam | Lorazepam | 860 | 69 |
| Mirtazapine | Mirtazapine | 846 | 86 |
| Potassium Chloride | Potassium Chloride | 802 | 98 |
| Omeprazole | Omeprazole | 795 | 126 |
| Furosemide | Furosemide | 790 | 112 |
| Carvedilol | Carvedilol | 762 | 142 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 755 | 125 |
| Losartan Potassium | Losartan Potassium | 738 | 119 |
| Memantine Hcl | Memantine Hcl | 724 | 39 |
| Montelukast Sodium | Montelukast Sodium | 699 | 125 |
| Alprazolam | Alprazolam | 692 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 692 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 686 | 137 |
| Metformin Hcl | Metformin Hcl | 682 | 146 |
| Hydralazine Hcl | Hydralazine Hcl | 628 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 563 | 110 |
| Quetiapine Fumarate | Quetiapine Fumarate | 557 | 38 |
| Clonazepam | Clonazepam | 548 | 55 |
| Famotidine | Famotidine | 547 | 71 |
| Tramadol Hcl | Tramadol Hcl | 497 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 479 | 74 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 425 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 385 | 80 |
| Trazodone Hcl | Trazodone Hcl | 363 | 65 |
| Diclofenac Sodium | Diclofenac Sodium | 359 | 74 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 354 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 352 | 71 |
| Allopurinol | Allopurinol | 328 | 41 |
| Sertraline Hcl | Sertraline Hcl | 323 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 307 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 305 | 66 |
| Ropinirole Hcl | Ropinirole Hcl | 296 | 37 |
| Chlorthalidone | Chlorthalidone | 280 | 62 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 280 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 278 | 40 |
| Pregabalin | Pregabalin | 269 | 46 |
| Ondansetron Hcl | Ondansetron Hcl | 250 | 70 |
| Prednisone | Prednisone | 246 | 124 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 246 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 245 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 243 | 71 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 243 | 17 |
| Diazepam | Diazepam | 242 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 234 | 45 |
| Simvastatin | Simvastatin | 224 | 39 |
| Mounjaro | Tirzepatide | 222 | 30 |
| Azithromycin | Azithromycin | 221 | 145 |
| Aripiprazole | Aripiprazole | 216 | 15 |
| Xarelto | Rivaroxaban | 212 | 18 |
| Buspirone Hcl | Buspirone Hcl | 208 | 26 |
| Ibuprofen | Ibuprofen | 205 | 61 |
| Atenolol | Atenolol | 204 | 36 |
| Glipizide | Glipizide | 204 | 32 |
| Finasteride | Finasteride | 199 | 44 |
| Spironolactone | Spironolactone | 197 | 34 |
| Ozempic | Semaglutide | 193 | 36 |
| Dicyclomine Hcl | Dicyclomine Hcl | 191 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 189 | 28 |
| Lactulose | Lactulose | 187 | 74 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 183 | 52 |
| Risperidone | Risperidone | 182 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 178 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 176 | 26 |
| Meloxicam | Meloxicam | 171 | 27 |
| Linzess | Linaclotide | 169 | 27 |
| Bupropion Hcl Sr | Bupropion Hcl | 168 | 30 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 167 | 19 |
| Nystatin | Nystatin | 164 | 67 |
| Januvia | Sitagliptin Phosphate | 140 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 140 | suppressed |
| Budesonide | Budesonide | 137 | 13 |
| Levetiracetam | Levetiracetam | 137 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 18 |
| Synthroid | Levothyroxine Sodium | 136 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 131 | 27 |
| Topiramate | Topiramate | 129 | 20 |
| Warfarin Sodium | Warfarin Sodium | 128 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 122 | 14 |
| Glimepiride | Glimepiride | 121 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 121 | 17 |
| Propranolol Hcl | Propranolol Hcl | 119 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 117 | 70 |
| Baclofen | Baclofen | 116 | 13 |
| Farxiga | Dapagliflozin Propanediol | 114 | 29 |
| Methocarbamol | Methocarbamol | 114 | 31 |
| Jardiance | Empagliflozin | 110 | 29 |
| Mupirocin | Mupirocin | 108 | 68 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 107 | 53 |
| Doxycycline Hyclate | Doxycycline Hyclate | 106 | 72 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 103 | 18 |
| Olanzapine | Olanzapine | 103 | suppressed |
| Trulicity | Dulaglutide | 103 | 22 |
| Clonidine Hcl | Clonidine Hcl | 102 | 29 |
| Entresto | Sacubitril/Valsartan | 102 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 102 | 20 |
| Latanoprost | Latanoprost | 100 | suppressed |
| Lansoprazole | Lansoprazole | 97 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 96 | 16 |
| Valsartan | Valsartan | 95 | suppressed |
| Sotalol | Sotalol Hcl | 92 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 88 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 13 |
| Amoxicillin | Amoxicillin | 84 | 65 |
| Amantadine | Amantadine Hcl | 82 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 80 | 18 |
| Estradiol | Estradiol | 79 | 24 |
| Formoterol Fumarate | Formoterol Fumarate | 78 | suppressed |
| Digoxin | Digoxin | 77 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 76 | 31 |
| Metformin Hcl Er | Metformin Hcl | 76 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 76 | 14 |
| Fluconazole | Fluconazole | 74 | 48 |
| Oxybutynin Chloride | Oxybutynin Chloride | 73 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 18 |
| Bumetanide | Bumetanide | 72 | 18 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 71 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 70 | 14 |
| Ketoconazole | Ketoconazole | 70 | 29 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 67 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 66 | suppressed |
| Glipizide Er | Glipizide | 66 | 15 |
| Meclizine Hcl | Meclizine Hcl | 65 | 39 |
| Oxcarbazepine | Oxcarbazepine | 65 | suppressed |
| Cephalexin | Cephalexin | 63 | 48 |
| Cilostazol | Cilostazol | 63 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 63 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 63 | suppressed |
| Colchicine | Colchicine | 62 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 61 | suppressed |
| Perphenazine | Perphenazine | 61 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 60 | 15 |
| Naloxone Hcl | Naloxone Hcl | 60 | 49 |
| Testosterone Cypionate | Testosterone Cypionate | 60 | suppressed |
| Hydrocortisone | Hydrocortisone | 59 | 18 |
| Promethazine Hcl | Promethazine Hcl | 59 | 17 |
| Ranolazine Er | Ranolazine | 59 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 59 | suppressed |
| Celecoxib | Celecoxib | 58 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 58 | suppressed |
| Roflumilast | Roflumilast | 57 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 54 | 13 |
| Admelog Solostar | Insulin Lispro | 53 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 53 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 53 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 52 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 52 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | 12 |
| Erythromycin | Erythromycin Base | 50 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 49 | suppressed |
| Methotrexate | Methotrexate Sodium | 49 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Brilinta | Ticagrelor | 48 | suppressed |
| Nitroglycerin | Nitroglycerin | 48 | 26 |
| Spiriva Handihaler | Tiotropium Bromide | 47 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 47 | suppressed |
| Ezetimibe | Ezetimibe | 45 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 45 | 45 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 43 | 43 |
| Lovastatin | Lovastatin | 42 | 11 |
| Movantik | Naloxegol Oxalate | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 40 | 15 |
| Brimonidine Tartrate | Brimonidine Tartrate | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Cefdinir | Cefdinir | 39 | 29 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Dutasteride | Dutasteride | 38 | suppressed |
| Febuxostat | Febuxostat | 38 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 38 | 20 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 38 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 25 |
| Lidocaine | Lidocaine | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 36 | suppressed |
| Torsemide | Torsemide | 36 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 35 | suppressed |
| Cyclosporine | Cyclosporine | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 31 |
| Spiriva Respimat | Tiotropium Bromide | 34 | suppressed |
| Lubiprostone | Lubiprostone | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Methadone Hcl | Methadone Hcl | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 31 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Fentanyl | Fentanyl | 28 | suppressed |
| Nystop | Nystatin | 28 | 16 |
| Phenobarbital | Phenobarbital | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 26 | suppressed |
| Humulin R | Insulin Regular, Human | 26 | suppressed |
| Zonisamide | Zonisamide | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Morphine Sulfate | Morphine Sulfate | 22 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Tretinoin | Tretinoin | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 12 |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | 13 |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 15 |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Sulfacetamide Sodium | Sulfacetamide Sodium | 17 | suppressed |
| Acetazolamide | Acetazolamide | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 15 | 13 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 14 | 11 |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | 12 |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,616.21 · 91 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, AREXVY, Auvelity, CAPLYTA, ELIQUIS, FANAPT, FARXIGA, HETLIOZ, INGREZZA, JARDIANCE, JOURNAVX, Kerendia, LEQVIO, MINIMED 780G, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, UBRELVY, VRAYLAR, XYOSTED, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error